Nuveen LLC Takes Position in Charles River Laboratories International, Inc. $CRL

Key Points

• Nuveen LLC has acquired 123,160 shares of Charles River Laboratories International, valued at approximately $18.5 million, increasing its stake to 0.25% of the company.
• Analysts have generally positive views on the stock, with several upgrades to a "buy" rating and an average price target of $175.69.
• In the latest quarter, Charles River Laboratories reported earnings per share of $3.12, exceeding analysts' expectations, with reported revenue of $1.03 billion.

Nuveen LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 123,160 shares of the medical research company's stock, valued at approximately $18,538,000. Nuveen LLC owned 0.25% of Charles River Laboratories International as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Teacher Retirement System of Texas purchased a new position in shares of Charles River Laboratories International in the 1st quarter valued at about $1,231,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Charles River Laboratories International by 15.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,118 shares of the medical research company's stock worth $952,000 after purchasing an additional 817 shares during the last quarter. Janney Montgomery Scott LLC lifted its stake in Charles River Laboratories International by 13.1% during the first quarter. Janney Montgomery Scott LLC now owns 44,500 shares of the medical research company's stock worth $6,698,000 after purchasing an additional 5,148 shares during the last quarter. GAMMA Investing LLC lifted its stake in Charles River Laboratories International by 61.6% during the first quarter. GAMMA Investing LLC now owns 1,398 shares of the medical research company's stock worth $210,000 after purchasing an additional 533 shares during the last quarter. Finally, Concurrent Investment Advisors LLC purchased a new stake in Charles River Laboratories International during the first quarter worth approximately $213,000. Hedge funds and other institutional investors own 98.91% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on CRL. Evercore ISI boosted their target price on Charles River Laboratories International from $180.00 to $190.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Wall Street Zen cut Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a research note on Sunday, August 17th. TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price for the company in a research note on Wednesday, May 14th. Robert W. Baird boosted their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research note on Thursday, May 8th. Finally, Citigroup upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $150.00 to $200.00 in a research note on Wednesday, July 9th. Five equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $175.69.

Charles River Laboratories International Stock Performance

CRL traded up $2.1940 during trading on Monday, hitting $164.0340. 702,668 shares of the stock were exchanged, compared to its average volume of 971,944. The firm has a market capitalization of $8.07 billion, a P/E ratio of -123.33, a PEG ratio of 5.16 and a beta of 1.48. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $230.02. The stock has a fifty day moving average price of $157.92 and a two-hundred day moving average price of $148.53. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.50 by $0.62. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The firm's revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.80 earnings per share. As a group, sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Activity

In other news, EVP Joseph W. Laplume sold 800 shares of the business's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the transaction, the executive vice president owned 24,116 shares of the company's stock, valued at approximately $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).